Date of Publication: Apr 2017
Bora, E., Akdede, B. B., Alptekin, K.
Background. Individuals with schizophrenia are at greater risk for metabolic syndrome (MetS) which is associated with cognitive deficits in the general population. MetS might be potentially an important contributing factor to cognitive impairment in schizophrenia. Method.
Date of Publication: Apr 2017
Galiabovitch, E., Hovens, C. M., Peters, J. S., Costello, A. J., Battye, S., Norden, S., Ryan, A., Corcoran, N. M.

Objective To evaluate the significance of routinely reported 'equivocal' lymphovascular invasion (LVI) in prostatectomy specimens of patients with clinically localized prostate cancer.

Date of Publication: Apr 2017
Kalincik, T., Brown, J. W. L., Robertson, N., Willis, M., Scolding, N., Rice, C.
Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown.
Date of Publication: Apr 2017
Mir, M. C., Derweesh, I., Porpiglia, F., Zargar, H., Mottrie, A., Autorino, R.
Background: Partial nephrectomy (PN) is the reference standard of management for a cT1a renal mass. However, its role in the management of larger tumors (cT1b and cT2) is still under scrutiny.
Date of Publication: Apr 2017
Rapado-Castro, M., Dodd, S., Bush, A. I., Malhi, G. S., Skvarc, D. R., On, Z. X., Berk, M., Dean, O. M.
Background. Cognitive deficits are predictors of functional outcome in patients with psychosis. While conventional anti-psychotics are relatively effective on positive symptoms, their impact on negative and cognitive symptoms is limited.
Date of Publication: Apr 2017
Ratheesh, A., Davey, C., Hetrick, S., Alvarez-Jimenez, M., Voutier, C., Bechdolf, A., McGorry, P. D., Scott, J., Berk, M., Cotton, S. M.
Objective: Some people with major depressive disorder (MDD) may be at a pre-onset stage for bipolar disorder (BD), where early identification or prevention efforts may be feasible.
Date of Publication: Mar 2017
Bryant, R. A., Gallagher, H. C., Gibbs, L., Pattison, P., MacDougall, C., Harms, L., Block, K., Baker, E., Sinnott, V., Ireton, G., Richardson, J.,...
Objective: Although disasters are a major cause of mental health problems and typically affect large numbers of people and communities, little is known about how social structures affect mental health after a disaster.
Date of Publication: Mar 2017
Cadavid, D., Balcer, L., Galetta, S., Aktas, O., Ziemssen, T., Vanopdenbosch, L., Frederiksen, J., Skeen, M., Jaffe, G. J., Butzkueven, H.,...
Background The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) has shown remyelinating activity in preclinical studies. We therefore assessed the safety and tolerability, and efficacy of opicinumab given soon after a first acute optic neuritis episode.